Tissue Bank

组织库核心C将提供必要的机制，以收集和分发来自大样本的组织。 将患者数量分配给各个研究者。由于Ph阴性MPD相对罕见，因此个体 单个机构的研究人员无法从足够多的患者中获得组织， 在合理的时间范围内得出统计学上有效的结论，无组织芯C。组织芯C将 提供来自处于这些疾病的不同阶段的大量患者的组织，以及来自 在疾病进展期间纵向收集个体患者。因此，组织库核心C将是 是当前和未来MPD研究的宝贵工具。 组织库核心C的具体目标是： 1)接收、处理和储存来自MPD联盟临床研究中心诊断的MPD患者的组织 以一种有效和有组织的方式。2)为MPD组织提供一个中央储存库， 基本数据由生物统计和数据管理核心B存储。这些数据将包括临床 实验室数据和家庭人口统计学，这将使选择和分布的组织最适合 每个翻译研究项目。3)使MPD随时可以获得有活力的冷冻组织 研究联合会调查员。当可用时，组织也将提供给科学家， 整个社区。4)进行生物标志物测定，旨在预测疾病进展和血栓形成 并发症，在诊断时收到的MPD样本，并定期在治疗期间。 组织库核心C的功能是：1）采集Ph阴性MPD组织，2）作为储存库 对于Ph阴性MPD组织，3）分发MPD组织研究，和4）进行生物标志物分析。 收集的组织将提供给MPD联盟成员和科学界，网址为： 大.组织库核心C将大大促进转化研究，这将提高诊断和 MPD的分期，并最终导致分子靶向治疗的发展。 PV和IM是目前没有有效治疗方法的疾病。PV和IM主要影响 年龄> 50岁的患者，其年发病率估计为2.8/100，000和0.4/100，000， 分别50岁以上的人越来越多，因此， 会受到这些疾病的影响。因此，从公共卫生的角度来看， 开发有效的治疗方法。

The Tissue Bank Core C will provide the necessary mechanism to collect and distribute tissues from large numbers of patients to individual investigators. Because Ph negative MPD are relatively rare, individua investigators at a single institution cannot obtain tissues from sufficiently large numbers of patients to reach statistically valid conclusions within a reasonable time frame without Tissue Core C. Tissue Core C will provide tissues from large cohorts of patients at various stages of these disorders, as well as tissues from individual patients collected longitudinally during disease progression. Thus, the Tissue Bank Core C will be an invaluable tool to current and future studies on MPD. The specific aims of the Tissue Bank Core C are to: 1) Receive, process, and store tissues from MPD patients diagnosed at MPD Consortium clinical sites in an efficient and organized way. 2) Provide a central repository for MPD tissues that can be associated with basic data to be stored by Biostatistics and Data Management Core B. These data will include clinical laboratory data and familial demographics that will enable selection and distribution of tissues best suited for each translational research project. 3) Make the viably frozen tissues readily available to the MPD Consortium investigators for research studies. When available, tissues will also be available to the scientific community at large. 4) Perform biomarker assays, designed to predict disease progression and thrombotic complications, on MPD samples received at the time of diagnosis, and periodically during therapy. The functions of Tissue Bank Core C will be to: 1) acquire Ph negative MPD tissues, 2) act as a repository for the Ph negative MPD tissues, 3) distribute the MPD tissues research, and 4) perform biomarker analyses. Tissues collected will be available to members of the MPD Consortium and to the scientific community at large. Tissue Bank Core C will significantly facilitate translational research that will enhance diagnosis and staging of MPD and ultimately lead to the development of molecularly targeted therapies. PV and IM are disorders for which there are currently no effective treatments. PV and IM affect primarily patients > 50 years of age and their annual incidences are estimated to be 2.8 and 0.4/100,000 people, respectively. The number of people over the age of 50 is increasing and therefore more people will be affected by these disorders in the future. Therefore, from a public health perspective it is imperative to develop effective therapies.